Our Leadership

Our team has secured multiple FDA approvals for medical devices and pharmaceuticals, as well as a number of venture exits. We have appointed experienced Fund Managers. The team is made up of:


Dr. James Williams –  James has a wealth of experience in a number of different industries, making him a valuable asset to the team. He is, and has been CEO of multiple medical device, drug discovery and development companies – both public and private.


Ms. Liddy McCall ­– Liddy has over 10 years experience in technology commercialisation. Her experience includes working with biotech companies involved in drug discovery, formulation and repositioning. Liddy has been admitted as a barrister and solicitor in a number of Australian jurisdictions and has worked as a lawyer and in funds management.


Mr. Gary Cox – Gary has worked in the IP profession since 1990, taking up his position at Wrays in 1994. He is involved in an array of areas that involve biotechnology and pharmaceuticals. He has also been retained to act in a number of leading contention matters and has received recognition for his work in patent prosecution.


Mr. Todd Shand – Todd works heavily in the areas of validity and infringement opinions as well as contentious issues including oppositions and revocation actions in Australia and New Zealand. He has a strong understanding of the latest judicial interpretations of the key legal principles in both jurisdictions.


Mr. Robert Pierce – Robert is Chief Executive Office at Wrays. Prior to his role as CEO, Rob held the position of CFO at Wrays and has also previously held several senior financial management roles in the UK at both listed and private businesses across a variety of industries including construction, utilities, manufacturing, retail and distribution. This background has given Robert broad industry experience that enables him to drive culture at Wrays to deliver robust, relevant and commercial solutions that best support client needs.